|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Investment in life insurance policies, at fair value | ||||||||||||||||||||
| Life insurance policy benefits receivable, net | ||||||||||||||||||||
| Loan receivables | ||||||||||||||||||||
| Loans receivable, net of unearned income | ||||||||||||||||||||
| Loans receivable, net of discount | ||||||||||||||||||||
| Allowance for loan losses | ||||||||||||||||||||
| Loans receivable, net | ||||||||||||||||||||
| Fees receivable | ||||||||||||||||||||
| Investment in alternative assets, at fair value | ||||||||||||||||||||
| Equity method investments | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES & STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Amended and Restated Senior credit facility with LNV Corporation | ||||||||||||||||||||
| Senior credit facilities with LNV Corporation and National Founders LP | ||||||||||||||||||||
| L Bonds | ||||||||||||||||||||
| Seller Trust L Bonds | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Total debt due to related parties | ||||||||||||||||||||
| Interest and dividends payable | ||||||||||||||||||||
| Other accrued expenses | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Repurchase option | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Deferred tax liability, net | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Redeemable noncontrolling interests | ||||||||||||||||||||
| Redeemable noncontrolling interests | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| REDEEMABLE PREFERRED STOCK (par value $0.001; shares authorized 100,000; shares outstanding 69,756 and 84,636; liquidation preference of $70,163 and $85,130 as of March 31, 2020 and December 31, 2019, respectively) | ||||||||||||||||||||
| SERIES 2 REDEEMABLE PREFERRED STOCK (par value $0.001; shares authorized 150,000; shares outstanding 146,812 and 147,164; liquidation preference of $147,668 and $148,023 as of March 31, 2020 and December 31, 2019, respectively) | ||||||||||||||||||||
| Redeemable preferred stock | ||||||||||||||||||||
| Redeemable Preferred Stock | ||||||||||||||||||||
| Series 2 Redeemable Preferred Stock | ||||||||||||||||||||
| Common stock | ||||||||||||||||||||
| (par value $0.001; shares authorized 210,000,000; shares issued and outstanding, 33,097,118 and 33,094,664 as of September 30, 2021 and December 31, 2020, respectively) | ||||||||||||||||||||
| Common stock in treasury, at cost (12,337,264 shares as of both September 30, 2021 and December 31, 2020) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| TOTAL GWG HOLDINGS STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| TOTAL STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Common stock, issued (in shares) | ||||||||||||||||||||
| Common stock, outstanding (in shares) | ||||||||||||||||||||
Loading...
